Overview

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Status:
Not yet recruiting
Trial end date:
2027-04-20
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation